P2Y6R与CYSLTR2一起作为动脉样硬化中长链胺的内源受体
1International Joint Research Centre On Purinergic Signalling, School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
新的研究确定了特定的受体,P2Y6R和CYSLTR2,作为胺诱导的动脉样硬化心血管疾病 (ASCVD) 的关键驱动因素. 准这些受体为ASCVD提供了一个新的治疗策略,超出了传统的降脂治疗.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 动脉样性心血管疾病 (ASCVD) 是一个主要的全球健康问题.
- 胺在ASCVD病原体中的作用越来越被认可.
- 现有的疗法主要侧重于降脂,突出显示需要新的治疗点.
研究的目的:
- 为了确定胺诱导的ASCVD的关键分子媒介.
- 为了阐明胺驱动动动脉硬化所涉及的信号通路.
- 探索针对特定受体的ASCVD新型治疗策略.
主要方法:
- 确定P2Y6受体 (P2Y6R) 和cysteinyl leukotriene受体2 (CYSLTR2) 作为关键介质.
- 研究胺与P2Y6R和CYSLTR2.2的结合.
- 对Gαq信号通路激活的分析.
- 对NLRP3炎症酶激活和IL-1β释放的评估.
- 血陶化物水平与ASCVD风险的相关性.
主要成果:
- 血陶酸与P2Y6R和CYSLTR2结合,激活Gαq通路.
- 这种激活会触发NLRP3炎症酶组合和IL-1β释放.
- 胺-P2Y6R/CYSLTR2轴加速动脉样硬化的进展.
- 长链胺被确定为ASCVD风险的潜在临床预测因素.
结论:
- 在胺诱导的ASCVD中,P2Y6R和CYSLTR2是关键受体.
- 向胺-CYSLTR2/P2Y6R复合体提供了一个新的治疗途径.
- 这种方法为ASCVD管理提供了超越传统降脂疗法的潜在策略.
更多相关视频
11:47Real-time Live-cell Flow Cytometry to Investigate Calcium Influx, Pore Formation, and Phagocytosis by P2X7 Receptors in Adult Neural Progenitor Cells
Published on: April 3, 2019
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Transducer Mechanism: G Protein–Coupled Receptors
GPCRs are also called heptahelical,...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Amplifying Signals via Second Messengers
IP3/DAG Signaling Pathway
